TransUnion
TRU
$70.70
+3.60%
TransUnion is one of the three dominant credit bureaus in the United States, providing consumer credit information, fraud detection, marketing, and analytical services globally. The company operates as an established oligopoly player alongside Equifax and Experian, leveraging its vast data assets and analytical capabilities to serve financial institutions and other businesses. The current investor narrative is shaped by its strategic expansion into international markets, as evidenced by its recent acquisition of majority ownership in Mexico's Buró de Crédito, and the ongoing debate centers on its ability to maintain growth and profitability in a competitive landscape where rivals are also investing in advanced data and AI tools.…
TRU
TransUnion
$70.70
Related headlines
Investment Opinion: Should I buy TRU Today?
Rating & Thesis: Hold. TRU presents a 'show me' story where the potential reward from its low forward P/E is balanced by significant near-term execution risks and poor technical momentum. The analyst consensus leans cautiously bullish but is in a 'wait-and-see' mode, awaiting clearer catalysts.
Supporting Evidence: The primary valuation appeal is the forward P/E of 12.64x, which is reasonable if the company hits its estimated EPS of $7.77. This is supported by strong free cash flow generation of $661.6M TTM and a solid Q4 operating margin of 17.38%. However, these positives are counteracted by decelerating revenue growth, high trailing P/E of 36.60x, and severe technical underperformance (-15.54% YoY). The stock trades just 10% above its 52-week low, reflecting deep skepticism.
Risks & Conditions: The two biggest risks are a failure to re-accelerate revenue growth and a miss on forward EPS targets, which would shatter the forward valuation thesis. This Hold rating would upgrade to a Buy if the stock sustains a break above the $78.55 resistance level on improving revenue momentum, or if the forward P/E compresses further toward 10x. It would downgrade to a Sell on a confirmed break below the $65.24 support. The stock is currently fairly valued for the risks it presents, trading at a premium to its own history on a trailing basis but a discount on forward expectations.
Sign up to view all
TRU 12-Month Price Forecast
The investment thesis for TRU hinges entirely on the company bridging the chasm between its high trailing valuation and its low forward multiple by delivering on promised earnings growth. The fundamental tools are present—strong cash flow, oligopoly position, and strategic international moves—but the recent growth plateau and terrible technicals cannot be ignored. The neutral stance reflects this standoff between value and momentum. The stance would upgrade to bullish on a sustained breakout above $78.55 with confirming volume, signaling a trend reversal. It would downgrade to bearish on a breakdown below $65.24, which would invalidate the value-support thesis and likely lead to further de-rating.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on TransUnion's 12-month outlook, with a consensus price target around $91.91 and implied upside of +30.0% versus the current price.
Average Target
$91.91
6 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
6
covering this stock
Price Range
$57 - $92
Analyst target range
A limited set of six analysts provide coverage for the stock, with recent institutional ratings showing a mix of 'Buy'/'Overweight' (from Needham, Stifel, Wells Fargo, Morgan Stanley) and 'Neutral'/'Equal Weight' (from Goldman Sachs and Barclays) actions, all of which have been reaffirmed. The consensus leans cautiously bullish. Analyst estimates point to an average EPS of $7.77 and average revenue of $6.50 billion for the coming period, but a specific consensus price target and Buy/Hold/Sell distribution are not provided in the data, making an implied upside calculation impossible. The estimated EPS range is wide, from a low of $7.34 to a high of $8.75, indicating a degree of uncertainty about the earnings recovery trajectory. The high target likely assumes successful execution on international acquisitions like Buró de Crédito, margin expansion, and a re-acceleration of growth. The low target likely factors in persistent competitive pressures, economic sensitivity, and integration risks. The recent pattern of reiterated ratings, rather than upgrades or downgrades, suggests analysts are in a 'wait-and-see' mode following the stock's decline, awaiting clearer fundamental catalysts.
Bulls vs Bears: TRU Investment Factors
The evidence presents a balanced but tense investment case. The bearish technicals and decelerating revenue momentum are currently more compelling, as they reflect real-time market sentiment and fundamental headwinds. However, the bullish arguments centered on cash flow, forward valuation, and strategic expansion provide a solid foundation for a potential recovery if execution improves. The single most important tension in the investment debate is whether the company can achieve the substantial earnings recovery implied by its low forward P/E of 12.64x, or if the elevated trailing P/E of 36.60x more accurately reflects a business facing sustained growth challenges. The resolution of this earnings trajectory will determine the stock's direction.
Bullish
- Strong Free Cash Flow Generation: The company generated $661.6 million in trailing twelve-month free cash flow, providing significant internal funding for growth, dividends, and share repurchases. This robust cash generation underpins financial flexibility and shareholder returns despite the stock's price decline.
- Attractive Forward Valuation: The forward P/E ratio of 12.64x, based on estimated EPS of $7.77, suggests a reasonable valuation if earnings targets are met. This represents a significant discount to the elevated trailing P/E of 36.60x and implies the market is pricing in a substantial earnings recovery.
- Strategic International Expansion: The recent acquisition of majority ownership in Mexico's Buró de Crédito strengthens TransUnion's Latin American footprint and offers a clear path for international growth. This strategic move diversifies revenue beyond the core U.S. market, which contributed $918.9 million in Q4 2025.
- Solid Profitability and Margins: The company maintains solid profitability with a Q4 2025 net margin of 8.64% and an operating margin of 17.38%. Gross margin for the quarter was a healthy 59.35%, demonstrating the underlying strength of its business model despite quarterly fluctuations.
Bearish
- Revenue Growth Deceleration: Sequential quarterly revenue growth has plateaued, with Q4 2025 revenue of $1.171B showing minimal increase from Q3's $1.170B. Year-over-year growth of 12.98% is positive but the momentum has stalled, raising concerns about the company's ability to re-accelerate top-line expansion.
- Elevated Trailing Valuation: The trailing P/E ratio of 36.60x is high and sits near the upper end of its own historical range, suggesting the market is not pricing in deep pessimism despite the stock's 15.54% annual decline. This leaves little margin for error if forward earnings estimates are missed.
- Pronounced Technical Downtrend: The stock is in a clear downtrend, down 15.54% over the past year and 10.74% over the past three months, significantly underperforming the S&P 500. Trading near its 52-week low of $65.24 indicates persistent selling pressure and a lack of bullish conviction.
- High Volatility and Market Sensitivity: With a beta of 1.707, TRU is approximately 71% more volatile than the broader market, amplifying downside risk during market corrections. This high volatility necessitates careful risk management and makes the stock unsuitable for risk-averse investors.
TRU Technical Analysis
The stock is in a pronounced downtrend, having declined 15.54% over the past year and currently trading at $70.53, which is near the lower end of its 52-week range of $65.24 to $99.39. This positioning, approximately 10% above the 52-week low, suggests the stock is in a value-seeking zone but remains under significant selling pressure, having experienced a maximum drawdown of -33.72% during the period. Recent momentum shows a modest short-term bounce, with the stock up 2.53% over the past month, yet this is a stark underperformance compared to the S&P 500's 9.98% gain, as indicated by a relative strength of -7.45. The 3-month performance remains deeply negative at -10.74%, indicating the longer-term downtrend is still dominant and the recent uptick may be a temporary relief rally within a broader bearish structure. Key technical levels are clearly defined, with immediate support at the 52-week low of $65.24 and major resistance at the 52-week high of $99.39. A decisive break below the $65 support could trigger a new leg down, while a sustained move above the recent local highs near $78.55 would be necessary to signal a potential trend reversal. The stock exhibits high volatility with a beta of 1.707, meaning it is approximately 71% more volatile than the broader market, which amplifies both risk and potential reward and necessitates careful position sizing for risk management.
Beta
1.57
1.57x market volatility
Max Drawdown
-33.7%
Largest decline past year
52-Week Range
$65-$99
Price range past year
Annual Return
-16.1%
Cumulative gain past year
| Period | TRU Return | S&P 500 |
|---|---|---|
| 1m | +2.5% | +11.4% |
| 3m | +0.7% | +8.3% |
| 6m | -12.2% | +9.4% |
| 1y | -16.1% | +31.3% |
| ytd | -15.2% | +7.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
TRU Fundamental Analysis
Revenue growth has been positive but shows signs of deceleration; the most recent Q4 2025 revenue was $1.171 billion, representing a 12.98% year-over-year increase. However, sequential quarterly revenue from Q1 to Q4 2025 shows a pattern of $1.096B, $1.140B, $1.170B, and $1.171B, indicating growth momentum has plateaued in the latter half of the year. The U.S. Markets segment, contributing $918.9 million in the latest period, remains the primary growth driver, while the International segment contributed $255.8 million. The company is profitable, with Q4 2025 net income of $101.2 million and a net margin of 8.64%. Gross margin for the quarter was a healthy 59.35%, but this has fluctuated significantly between quarters, from a low of 46.24% in Q2 2025 to the recent 59.35%, suggesting potential volatility in cost structures or revenue mix. Operating margin for Q4 2025 was 17.38%, showing the company converts a solid portion of revenue to operating profit. Balance sheet health is moderate, with a debt-to-equity ratio of 1.16, indicating a leveraged but manageable capital structure. The company generates substantial cash flow, with trailing twelve-month free cash flow of $661.6 million, providing ample internal funding for growth initiatives, dividends, and share repurchases. Return on equity stands at 10.26%, which is acceptable but not exceptional, reflecting the returns generated on shareholder capital.
Quarterly Revenue
$1.2B
2025-12
Revenue YoY Growth
+0.12%
YoY Comparison
Gross Margin
+0.59%
Latest Quarter
Free Cash Flow
$661600000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is TRU Overvalued?
Given the positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE is elevated at 36.60x, while the forward PE is significantly lower at 12.64x, based on estimated EPS of $7.77. This large gap implies the market is pricing in a substantial recovery in earnings over the next twelve months, with the forward multiple suggesting a more reasonable valuation if those estimates are achieved. Compared to sector averages, the stock's trailing PE of 36.60x is likely at a premium, though specific industry average data is not provided in the valuation data block. The forward PE of 12.64x, however, would likely represent a discount if the sector average is higher, hinging entirely on the company's ability to hit its forward EPS targets. The premium/discount justification rests on TransUnion's oligopoly position and cash flow generation, but is tempered by its recent growth deceleration. Historically, the current trailing PE of 36.60x sits above the multi-quarter range observed in the historical ratios data, which has fluctuated from the high 20s to over 70x in recent years. This places the valuation near the upper end of its own historical band, suggesting the market is not pricing in deep pessimism despite the stock's price decline, and expectations for a profit recovery are already embedded in the price.
PE
36.6x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range -11x~103x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
14.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: TransUnion faces risks from its leveraged balance sheet, with a debt-to-equity ratio of 1.16, which could pressure financial flexibility if interest rates remain elevated. Revenue growth deceleration, evidenced by plateauing sequential quarterly sales, poses a risk to the earnings recovery narrative priced into the forward P/E. Furthermore, significant volatility in gross margins (ranging from 46.24% to 59.35% over recent quarters) indicates potential instability in cost management or revenue mix, which could lead to earnings misses and jeopardize the forward valuation thesis.
Market & Competitive Risks: The stock's high beta of 1.707 makes it highly sensitive to broader market downturns, as seen in its -44.58 relative strength versus the S&P 500 over one year. Trading at a trailing P/E of 36.60x, which is near the upper end of its historical range, the stock is vulnerable to valuation compression if growth expectations are not met. Competitive risks are highlighted by news of rivals like Upstart and established peers investing in their own AI-driven tools, which could erode TransUnion's analytical service advantages over time.
Worst-Case Scenario: The most damaging scenario involves a failure to achieve forward EPS estimates, coupled with a broader market sell-off that disproportionately impacts high-beta stocks. This could trigger a break below the key technical support at the 52-week low of $65.24, leading to a cascade of analyst downgrades. In this adverse scenario, the stock could realistically revisit its maximum drawdown level of -33.72% from its recent trading range, implying a downside of approximately -25% to -30% from the current price of $70.53, targeting a range of $49 to $53.
FAQ
The key risks are, in order of severity: 1) Execution Risk: Failure to achieve the forward EPS of $7.77, which would cause the forward valuation thesis to collapse. 2) Growth Risk: Continued deceleration or plateauing of revenue growth, as seen in recent sequential quarters. 3) Market Risk: High stock-specific volatility with a beta of 1.707, meaning it will fall more than the market in a downturn, as evidenced by its -44.58 relative strength over the past year. 4) Competitive Risk: Erosion of its analytical service edge as rivals and fintechs like Upstart develop competing AI tools.
The 12-month forecast is bifurcated, with a 50% probability base case target range of $75-$85, assuming the company meets consensus EPS estimates of $7.77. The bullish case (30% probability) targets $90-$99 on successful execution and multiple expansion, while the bearish case (20% probability) sees a drop to $55-$65 on missed estimates and a break of key support. The most likely scenario is the base case, where the stock grinds higher as it proves it can deliver on current earnings expectations, but remains capped until revenue growth re-accelerates.
TRU presents a split valuation picture. On a trailing basis, it appears overvalued with a P/E of 36.60x, which is at the upper end of its historical range. On a forward basis, it appears undervalued or fairly valued with a P/E of 12.64x based on expected earnings growth. This dichotomy means the market is pricing in a substantial earnings recovery. Therefore, the stock is fairly valued for the significant execution risk it carries; it is neither deeply undervalued nor egregiously overvalued, but priced for a specific—and uncertain—future outcome.
TRU is a speculative buy for investors with a higher risk tolerance and a patient horizon. The potential reward is anchored in its reasonable forward P/E of 12.64x if the company hits its $7.77 EPS target, offering significant upside if the earnings recovery materializes. However, it is not a good buy for risk-averse investors, given its high beta of 1.707, decelerating revenue momentum, and position in a pronounced technical downtrend. A good entry would be on a confirmed technical reversal above $78.55, which would signal a break in the bearish trend.
TRU is unsuitable for short-term trading due to its high volatility and lack of a clear near-term catalyst; traders would be fighting a strong downtrend. It is more appropriate for a long-term (2+ year) investment horizon, allowing time for its international expansion strategy to bear fruit and for the earnings recovery narrative to play out. The company's strong free cash flow generation and dividend (0.54% yield) support a long-term holding period. Given the current uncertainty, investors should be prepared to hold through potential further volatility.